ENDPOINTS

RFK won’t testify before key Senate committee this week...

HHS Secretary Robert F. Kennedy won’t be appearing before a Senate panel on Thur...

Stock market melts down over Trump’s tariffs, and biote...

As President Donald Trump’s tariffs roil financial markets, biopharma is no exce...

As stock market melts down over Trump’s tariffs, biotec...

As President Donald Trump’s tariffs roil financial markets, biopharma is no exce...

RayThera secures $110M in Series A raise

RayThera has collected $110 million in a Series A raise to help it advance a pre...

Lexeo discloses new data for heart drug; Spark Therapeu...

Plus, news about Kashiv BioSciences: Lexeo Therapeutics reveals early data f...

ADC startup DualityBio seeks Hong Kong IPO amid precari...

Multi-partnered ADC startup Duality Biologics is moving forward with its initial...

Rhythm touts Phase 3 win for rare obesity drug in peopl...

Rhythm Pharmaceuticals is looking to expand the potential market for its rare ob...

Cell and gene therapy CDMO AmplifyBio shuts down over '...

Another CDMO has been hit by the slowdown of cell and gene therapy R&D. Ampl...

GSK’s newest neuro pact is with ABL Bio, a Sanofi-partn...

South Korean biotech ABL Bio has lined up another platform license agreement wit...

Q&A: David Liu talks about science under pressure, teas...

Gene editing pioneer David Liu was awarded one of three Breakthrough Prizes in L...

GLP-1 weight loss discoverers win Breakthrough Prize: Q...

Medicines based on glucagon-like peptide-1 (GLP-1) have revolutionized the treat...

Staff cuts sweep across FDA; Tariff rollout raises ques...

Welcome back to Endpoints Weekly! Much of this week’s headlines dealt with the f...

Trump administration leaves obesity coverage expansion ...

The Trump administration finalized new policies for some Medicare programs on Fr...

GSK and Pfizer resolve RSV vaccine patent fight

GSK and Pfizer have settled a lawsuit alleging Pfizer’s RSV shot Abrysvo infring...

Marks was asked to provide non-existent vaccine risk da...

Ousted FDA biologics and vaccine chief Peter Marks was asked to provide non-exis...

Novavax’s approval delay may signal warning for vaccine...

On the precipice of FDA approval, Novavax's Covid vaccine is now in limbo while ...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.